Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

574 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The PIRO concept: R is for response.
Gerlach H, Dhainaut JF, Harbarth S, Reinhart K, Marshall JC, Levy M. Gerlach H, et al. Among authors: reinhart k. Crit Care. 2003 Jun;7(3):256-9. doi: 10.1186/cc2195. Epub 2003 May 8. Crit Care. 2003. PMID: 12793881 Free PMC article. No abstract available.
Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012.
Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Deutschman CS, Machado FR, Rubenfeld GD, Webb S, Beale RJ, Vincent JL, Moreno R; Surviving Sepsis Campaign Guidelines Committee including The Pediatric Subgroup. Dellinger RP, et al. Among authors: reinhart k. Intensive Care Med. 2013 Feb;39(2):165-228. doi: 10.1007/s00134-012-2769-8. Epub 2013 Jan 30. Intensive Care Med. 2013. PMID: 23361625 Free PMC article.
Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: The RAMSES Study.
Reinhart K, Menges T, Gardlund B, Harm Zwaveling J, Smithes M, Vincent JL, Tellado JM, Salgado-Remigio A, Zimlichman R, Withington S, Tschaikowsky K, Brase R, Damas P, Kupper H, Kempeni J, Eiselstein J, Kaul M. Reinhart K, et al. Crit Care Med. 2001 Apr;29(4):765-9. doi: 10.1097/00003246-200104000-00015. Crit Care Med. 2001. PMID: 11373466 Clinical Trial.
Randomized trial evaluating serial protein C levels in severe sepsis patients treated with variable doses of drotrecogin alfa (activated).
Shorr AF, Janes JM, Artigas A, Tenhunen J, Wyncoll DL, Mercier E, Francois B, Vincent JL, Vangerow B, Heiselman D, Leishman AG, Zhu YE, Reinhart K; RESPOND investigators. Shorr AF, et al. Among authors: reinhart k. Crit Care. 2010;14(6):R229. doi: 10.1186/cc9382. Epub 2010 Dec 21. Crit Care. 2010. PMID: 21176144 Free PMC article. Clinical Trial.
Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study.
Abraham E, Reinhart K, Svoboda P, Seibert A, Olthoff D, Dal Nogare A, Postier R, Hempelmann G, Butler T, Martin E, Zwingelstein C, Percell S, Shu V, Leighton A, Creasey AA. Abraham E, et al. Among authors: reinhart k. Crit Care Med. 2001 Nov;29(11):2081-9. doi: 10.1097/00003246-200111000-00007. Crit Care Med. 2001. PMID: 11700399 Clinical Trial.
Tissue factor pathway inhibitor activity in severe sepsis.
Creasey AA, Reinhart K. Creasey AA, et al. Among authors: reinhart k. Crit Care Med. 2001 Jul;29(7 Suppl):S126-9. doi: 10.1097/00003246-200107001-00038. Crit Care Med. 2001. PMID: 11445747 Review.
574 results